BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15736963)

  • 1. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors.
    Cruchaga C; Odriozola L; Andréola M; Tarrago-Litvak L; Martínez-Irujo JJ
    Biochemistry; 2005 Mar; 44(9):3535-46. PubMed ID: 15736963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.
    Odriozola L; Cruchaga C; Andréola M; Dollé V; Nguyen CH; Tarrago-Litvak L; Pérez-Mediavilla A; Martínez-Irujo JJ
    J Biol Chem; 2003 Oct; 278(43):42710-6. PubMed ID: 12917424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.
    Villahermosa ML; Martinez-Irujo JJ; Cabodevilla F; Santiago E
    Biochemistry; 1997 Oct; 36(43):13223-31. PubMed ID: 9341211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.
    Cruchaga C; Anso E; Font M; Martino VS; Rouzaut A; Martinez-Irujo JJ
    Biochem J; 2007 Jul; 405(1):165-71. PubMed ID: 17355225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
    Xia Q; Radzio J; Anderson KS; Sluis-Cremer N
    Protein Sci; 2007 Aug; 16(8):1728-37. PubMed ID: 17656585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.
    Canard B; Sarfati SR; Richardson CC
    J Biol Chem; 1998 Jun; 273(23):14596-604. PubMed ID: 9603976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors.
    Mas A; Vázquez-Alvarez BM; Domingo E; Menéndez-Arias L
    J Mol Biol; 2002 Oct; 323(2):181-97. PubMed ID: 12381314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
    Song Y; Chan JM; Tovian Z; Secrest A; Nagy E; Krysiak K; Bergan K; Parniak MA; Oldfield E
    Bioorg Med Chem; 2008 Oct; 16(19):8959-67. PubMed ID: 18789701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.
    White EL; Parker WB; Ross LJ; Shannon WM
    Antiviral Res; 1993 Dec; 22(4):295-308. PubMed ID: 7506513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate.
    Cruchaga C; Ansó E; Rouzaut A; Martínez-Irujo JJ
    J Biol Chem; 2006 Sep; 281(38):27744-52. PubMed ID: 16829515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
    Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
    Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA
    J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance.
    Vaccaro JA; Anderson KS
    Biochemistry; 1998 Oct; 37(40):14189-94. PubMed ID: 9760256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.